Absci Corporation: ABS-101 Has Both First-Gen And Next-Gen Competitors
Source: SeekingAlpha
2025-09-17 06:08:57 ET
...
Read the full article on Seeking Alpha
For further details see:
Absci Corporation: ABS-101 Has Both First-Gen And Next-Gen Competitors
Spyre Therapeutics Inc.
NASDAQ: SYRE
SYRE Trading
1.62% G/L:
$40.73 Last:
195,554 Volume:
$40.92 Open:
SYRE Latest News
February 23, 2026 10:38:15 am
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million
February 19, 2026 04:02:00 pm
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
SYRE Stock Data
$2,603,991,883
65,619,664
1.61%
44
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
